CRA was retained by a Fortune 100 pharmaceutical company to assess the multi-year selection process associated with a recent acquisition. Working with the client CRA developed analyses to examine the impact decisions commonly associated with blending companies. The analyses incorporated different selection processes for areas of overlap, merger required spin-offs, as well as general workforce adjustments. CRA’s analyses provided a “real-time” review of the decisions as they were being made to address particular areas of risk.
CRA announces vice president promotions
CRA is proud to announce the promotions of four new vice presidents: Andrea Asoni in the Antitrust & Competition Practice; Rachel Berk in the Risk,...